Evaxion Biotech A/S (EVAX) Expected to Announce Quarterly Earnings on Wednesday

Evaxion Biotech A/S (NASDAQ:EVAX) will likely be issuing its quarterly earnings data before the market opens on Wednesday, March 26th. Analysts expect the company to announce earnings of ($0.26) per share and revenue of $1.66 million for the quarter.

Evaxion Biotech A/S Stock Down 0.5 %

Shares of NASDAQ:EVAX opened at $1.89 on Monday. Evaxion Biotech A/S has a 52-week low of $1.70 and a 52-week high of $22.05. The company has a market capitalization of $2.22 million, a PE ratio of -1.30 and a beta of -0.25. The company has a debt-to-equity ratio of 7.99, a quick ratio of 2.80 and a current ratio of 1.00. The company has a fifty day moving average of $2.59 and a 200-day moving average of $7.69.

Analysts Set New Price Targets

A number of analysts have recently commented on the company. HC Wainwright reissued a “buy” rating and set a $14.00 price target on shares of Evaxion Biotech A/S in a research note on Thursday, February 20th. Lake Street Capital reduced their target price on shares of Evaxion Biotech A/S from $35.00 to $6.00 and set a “buy” rating on the stock in a report on Tuesday, February 4th.

Evaxion Biotech A/S Company Profile

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers.